EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices

using neuroblocking technology to treat obesity, metabolic diseases

and other gastrointestinal disorders, today announced the completion

of the first commercial implants of the Maestro@ Rechargeable (RC)

System, delivering VBLOC@ vagal blocking therapy. The implants were

performed at Hadi Hospital in Kuwait City, Kuwait.

Dr. Jarallah, who performed the first commercial implant, said, "It is

an honor to be the first surgeon to implant the commercially-available

Maestro Rechargeable System. VBLOC Therapy is patient-oriented, in

that it does not force punitive, mechanical limits to lifestyle and

diet, or require surgical alteration of the anatomy. As the first

bariatric procedure to offer this positive path to weight loss, it

represents a revolutionary, neuroscience-based approach to the

treatment of obesity."

Dr. Jarallah added, "The surgeries proceeded without incident, and the

patients are all recovering very well."

The Maestro System is distributed by Bader Sultan & Brothers Co. in

the Gulf Coast Countries. Bader Sultan & Brothers Co. is a leading

distributor of medical and diagnostic equipment, headquartered in

Kuwait, with wide coverage throughout the Middle East.

"The first commercial implants of the Maestro RC System marks another

important step forward for EnteroMedics in our evolution as a

commercial organization and, more importantly, for the bariatric

community in the Gulf Coast Countries, who face a daunting obesity and

metabolic disease epidemic," said Mark B. Knudson, Ph.D.,

EnteroMedics' President and Chief Executive Officer. Dr. Knudson

added: "We are thrilled to now offer individuals in the GCC and

Australia the ability to choose a patient-friendly, long-term solution

for treating obesity."

About Maestro@ Rechargeable (RC) System

The Maestro RC System delivers VBLOC@ vagal blocking therapy via two

small electrodes that are laparoscopically implanted and placed in

contact with the trunks of the vagus nerve just above the junction

between the esophagus and the stomach. The Maestro RC System is

powered by an internal, rechargeable battery. The battery is recharged

via an external mobile charger and transmit coil that the patient uses

for a short time each week. The Maestro RC System has received CE Mark

and has been listed on the Australian Register of Therapeutic Goods.

About VBLOC@ Therapy

EnteroMedics developed VBLOC@ vagal blocking therapy to offer

bariatric surgeons and their patients a less invasive alternative to

existing surgical weight loss procedures that may present significant

risks and alter digestive system anatomy, lifestyle and food choices.

VBLOC Therapy is delivered via the Maestro@ Rechargeable System

through laparoscopically implanted leads to intermittently block the

vagus nerves using high-frequency, low-energy electrical impulses.

VBLOC Therapy is designed to target the multiple digestive functions

under control of the vagus nerves and to affect the perception of

hunger and fullness.

About Obesity in the Gulf Coast Countries

Obesity and metabolic disease is a significant issue in the Middle

East, where an estimated 13% of men and 24.5 % of women are obese,

according to the World Health Organization. Saudi Arabia, Kuwait,

Qatar and the United Arab Emirates each rank in the top 20 for global

prevalence of adult obesity (BMI ? 30 kg/m), with the obese

population ranging from 25-40% of the total population. In addition,

the incidence of diabetes, a co-morbidity of obesity, is epidemic

within the region.

About Bader Sultan & Brothers Co.

Bader Sultan & Brothers Co. is a leading distributor of medical and

diagnostic equipment, headquartered in Kuwait, with wide coverage

throughout the Middle East.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development

and commercialization of its neuroscience based technology to treat

obesity and metabolic diseases. EnteroMedics' proprietary technology,

VBLOC@ vagal blocking therapy, delivered by a pacemaker-like device

called the Maestro@ Rechargeable System, is designed to intermittently

block the vagus nerves using high-frequency, low-energy, electrical

impulses. VBLOC Therapy allows people with obesity to take a positive

path towards weight loss, addressing the lifelong challenge of obesity

and its comorbidities without sacrificing wellbeing or comfort. The

Maestro Rechargeable System has received CE Mark and is listed on the

Australian Register of Therapeutic Goods. For more information, visit

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about

EnteroMedics Inc. Our actual results could differ materially from

those discussed due to known and unknown risks, uncertainties and

other factors including our limited history of operations; our losses

since inception and for the foreseeable future; our lack of commercial

regulatory approval for our Maestro@ System for the treatment of

obesity in the United States or in any foreign market other than

Australia and the European Community; our preliminary findings from

our EMPOWER? pivotal trial; our ability to comply with the Nasdaq

continued listing requirements; our ability to commercialize our

Maestro System; our dependence on third parties to initiate and

perform our clinical trials; the need to obtain regulatory approval

for any modifications to our Maestro System; physician adoption of our

Maestro System and VBLOC@ vagal blocking therapy; our ability to

obtain third party coding, coverage or payment levels; ongoing

regulatory compliance; our dependence on third party manufacturers and

suppliers; the successful development of our sales and marketing

capabilities; our ability to raise additional capital when needed;

international commercialization and operation; our ability to attract

and retain management and other personnel and to manage our growth

effectively; potential product liability claims; potential healthcare

fraud and abuse claims; healthcare legislative reform; and our ability

to obtain and maintain intellectual property protection for our

technology and products. These and additional risks and uncertainties

are described more fully in the Company's filings with the Securities

and Exchange Commission, particularly those factors identified as

"risk factors" in the annual report on Form 10-K filed March 15, 2012.

We are providing this information as of the date of this press release

and do not undertake any obligation to update any forward-looking

statements contained in this document as a result of new information,

future events or otherwise.

Caution - Investigational device. Limited by Federal (United States)

law to investigational use.

The implantation procedure and usage of the Maestro@ System carry some

risks, such as the risks generally associated with laparoscopic

procedures and those related to treatment as described in the ReCharge

clinical trial informed consent.